Pedro Roda Navarro

Dr. Pedro Roda Navarro

Department of Immunology, Ophthalmology and ORL, Complutense University and “12 de Octubre” Health Research Institute, 28040 Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2017 in OncoImmunology
Verified
Journal Article
Open access
SHSeandean Lykke Harwood
Seandean Lykke Harwood
AAAna Alvarez-Cienfuegos
Ana Alvarez-Cienfuegos
NNNatalia Nuñez-Prado
Natalia Nuñez-Prado
MCMarta Compte
Marta Compte
SPSara Hernández Pérez
Sara Hernández Pérez
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor-penetrating capabilities of current bispecific antibody formats. Here, we have engineered the ATTACK (Asymmetric Tandem Trimerbody for T cell Activation and Cancer Killing), a novel T cell-recruiting bispecific antibody which combines three EGFR-binding single-domain antibodies (VHH; clone EgA1) with a single CD3-binding single-chain variable fragment (scFv; clone OKT3) in an intermediate molecular weight package. The two specificities are oriented in opposite directions in order to simultaneously engage cancer cells and T cell effectors, and thereby promote immunological synapse formation. EgA1 ATTACK was expressed as a homogenous, non-aggregating, soluble protein by mammalian cells and demonstrated an enhanced binding to EGFR, but not CD3, when compared to the previously characterized tandem bispecific antibody which has one EgA1 VHH and one OKT3 scFv per molecule. EgA1 ATTACK induced synapse formation and early signaling pathways downstream of TCR engagement at lower concentrations than the tandem VHH-scFv bispecific antibody. Furthermore, it demonstrated extremely potent, dose-dependent cytotoxicity when retargeting human T cells towards EGFR-expressing cells, with an efficacy over 15-fold higher than that of the tandem VHH-scFv bispecific antibody. These results suggest that the ATTACK is an ideal format for the development of the next-generation of T cell-redirecting bispecific antibodies.

7 February 2022 in OncoImmunology
Verified
Journal Article
Open access
ATAntonio Tapia-Galisteo
Antonio Tapia-Galisteo
ÍRÍñigo Sánchez Rodríguez
Íñigo Sánchez Rodríguez
OAOscar Aguilar-Sopeña
Oscar Aguilar-Sopeña
SHSeandean Lykke Harwood
Seandean Lykke Harwood
JNJavier Narbona
Javier Narbona
LSLaura Sanz
Laura Sanz
Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials. However, improvement of their efficacy and selectivity for solid tumors is still required. Here, we describe a novel tandem T-cell recruiting trispecific antibody for the treatment of colorectal cancer (CRC). This construct, termed trispecific T-cell engager (TriTE), consists of a CD3-specific single-chain Fv (scFv) flanked by anti-epidermal growth factor receptor (EGFR) and anti-epithelial cell adhesion molecule (EpCAM) single-domain VHH antibodies. The TriTE was well expressed in mammalian and yeast cells, bound the cognate antigens of the three parental antibodies, and enabled the specific cytolysis of EGFR- and/or EpCAM-expressing cancer cells, without inducing T cell activation and cytoxicity against double-negative (EGFR−EpCAM−) cancer cells. Bivalent bispecific targeting of double-positive HCT116 cells by TriTE improved in vitro potency up to 100-fold compared to single-positive cells and significantly prolonged survival in vivo. In addition, it was less efficient at killing single-positive target cells than the corresponding bispecific controls, leading to potentially enhanced tumor specificity. Moreover, dual targeting of two tumor-associated antigens may contribute toward preventing the tumor escape by antigen loss caused by selective pressures from conventional single-targeting T-cell engagers, and may help to overcome antigenic heterogeneity.

11 November 2022
Verified
Book Chapter
Closed access
CCC Carrasco-Padilla
C Carrasco-Padilla
OAO Aguilar-Sopeña
O Aguilar-Sopeña
AGAlvaro Gómez-Morón
Alvaro Gómez-Morón
SAS Alegre-Gómez
S Alegre-Gómez
FSFrancisco Sánchez-Madrid
Francisco Sánchez-Madrid
PNPedro Roda Navarro
Pedro Roda Navarro

10 January 2020 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
PNPedro Roda Navarro
Pedro Roda Navarro
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy

19 May 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
EGEva M. García-Cuesta
Eva M. García-Cuesta
JRJosé Miguel Rodríguez-Frade
José Miguel Rodríguez-Frade
SGSofía R. Gardeta
Sofía R. Gardeta
GDGianluca D’aGostino
Gianluca D’aGostino
PMPablo Martínez
Pablo Martínez
MMMario Mellado
Mario Mellado
Significance: New imaging-based approaches are incorporating new concepts to our knowledge of biological processes. The analysis of receptor dynamics involved in cell movement using single-particle tracking demonstrates that cells require chemokine-mediated receptor clustering to sense appropriately chemoattractant gradients. Here, we report that this process does not occur in T cells expressing CXCR4 R334X , a mutant form of CXCR4 linked to WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis). The underlaying molecular mechanism involves inappropriate actin cytoskeleton remodeling due to the inadequate β-arrestin1 activation by CXCR4 R334X , which alters its lateral mobility and spatial organization. These defects, associated to CXCR4 R334X expression, contribute to the retention of hematopoietic precursors in bone marrow niches and explain the severe immunological symptoms associated with WHIM syndrome.

25 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PNPedro Roda Navarro
Pedro Roda Navarro
PBPhilippe I Bastiaens
Philippe I Bastiaens
Balanced activity of protein tyrosine kinases and phosphatases (PTPs) controls tyrosine phosphorylation levels and, consequently, is needed to prevent pathologies like cancer. Phosphatase activity is tightly regulated in space and time. Thus, in order to understand how phospho-tyrosine signalling is regulated, the intracellular dynamics of PTPs should be investigated. Here, we have studied the intracellular dynamics of PTPD1, a FERM (four-point-one, ezrin, radixin, moesin) domain-containing PTP that is over expressed in cancer cells and potentiates EGFR signalling. Whereas PTPD1 was excluded from E-cadherin rich cell-cell adhesions in epithelial cell monolayers, it diffused from the cytoplasm to those membranes in contact with the extracellular medium. Localisation of PTPD1 at the plasma membrane was mediated by its FERM domain and enabled the formation of EGFR/PTPD1-containing signalling complexes that pre-existed at the plasma membrane before EGF stimulation. PTPD1 and EGFR transiently co-localised at EGF stimulation sites until the formation of macropinosomes containing active species of EGFR. Interference of PTPD1 expression caused a decrease in EGFR phosphorylated species at the periphery of the cell. Presented data suggest that the transient formation of dynamic PTPD1/EGFR signalling complexes strengthens EGF signalling by promoting the spatial propagation of EGFR phosphorylated species.